The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists

Oncologist

Volumn 16, Issue 11, 2011, Pages 1520-1526

  Joh, Jennifer E ^a   Esposito, Nicole N ^a,b   Kiluk, John V ^a   Laronga, Christine ^a   CATHERINE LEE, M ^a   Loftus, Loretta ^a   Soliman, Hatem ^a   Boughey, Judy C ^c   Reynolds, Carol ^c   Lawton, Homas J ^d   Acs, Peter I ^e   Gordan, Lucio ^e   Geza, Acs ^a,b,f  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c MAYO CLINIC   (United States)

^d Seattle Breast Pathology Consultants   (United States)

^e Florida Cancer Specialists   (United States)

^f Ruffolo Hooper and Associates   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Gene expression profiling; Risk assessment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER STAGING; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LYMPH VESSEL; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MITOSIS RATE; ONCOLOGICAL PARAMETERS; ONCOTYPE DX RECURRENCE SCORE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SCORING SYSTEM;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 82355164800     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0045     Document Type: Article

References (30)

1. EBCTCG: Effects of chemotherapy and hor-monal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-1717.
2. Turaga K, Acs G, Laronga C. Gene expression profiling in breast cancer. Cancer Control 2010;17: 177-182.
3. Ross JS, Hatzis C, Symmans WF et al. Com-mercialized multigene predictors of clinical out-come for breast cancer. The Oncologist 2008;13: 477-493.
4. Bao T, Davidson NE. Gene expression profil-ing of breast cancer. Adv Surg 2008;42:249-260.
5. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-2826.
6. Toi M, Iwata H, Yamanaka T et al. Clinical significance of the 21-gene signature (oncotype dx) in hormone receptor-positive early stage primary breast cancer in the japanese population. Cancer 2010;116:3112-3118.
7. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A transatac study. J Clin Oncol 2010;28:1829-1834.
8. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8:R25.
9. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
10. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
11. Mamounas EP, Tang G, Fisher B et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from nsabp b-14 and nsabp b-20. J Clin Oncol 2010;28:1677-1683.
12. Page DL, Anderson TJ, Sakamoto G, eds. In-filtrating carcinoma: major histologic types. London: WB Saunders, 1987:193-235.
13. Rosen PP, Oberman HA: Tumors of the mammary gland. Washington, DC: Armed Forces Institute of Pathology, 1993.
14. Pinder SE, Elston CW, Ellis IO, eds.: Invasive carcinoma-usual histologic types, 3rd ed. Edinburgh: Churchill Livingstone, 1998:283-337.
15. Elston CW, Ellis IO, eds.: Assessment of histologic grade, 3rd ed.: Edinburgh, Churchill Livingstone, 1998:365-384.
16. Lyman GH, Cosler LE, Kuderer NM et al. Impact of a 21-gene rt-pcr assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007;109:1011-1018.
17. Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969;24:1071-1080.
18. Adair F, Berg J, Joubert L et al. Long-term followup of breast cancer patients: the 30-year report. Cancer 1974;33:1145-1150.
19. Koscielny S, Tubiana M, Le MG et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 1984;49:709-715.
20. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
21. Hilsenbeck SG, Ravdin PM, de Moor CA et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52:227-237.
22. Flanagan MB, Dabbs DJ, Brufsky AM et al. Histopathologic variables predict oncotype dx recurrence score. Mod Pathol 2008;21:1255-1261.
23. Geradts J, Bean SM, Bentley RC et al. The oncotype dx recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010;28:969-977.
24. Lo SS, Mumby PB, Norton J et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28:1671-1676.
25. Henry LR, Stojadinovic A, Swain SM et al. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009;99:319-323.
26. Oratz R, Paul D, Cohn AL et al. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007;3:182-186.
27. Kamal A, Loprinzi C, Reynolds C et al. How well do standard prognostic criteria predict oncotype dx (odx) scores? J Clin Oncol 2007 (suppl; abstract 576);25:18s.
28. Rayhanabad JA, Difronzo LA, Haigh PI et al. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm. Am Surg 2008;74:887-890.
29. Asad J, Jacobson AF, Estabrook A et al. Does oncotype dx recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 2008;196:527-529.
30. Sparano JA. Tailorx: trial assigning individualized options for treatment (rx). Clin Breast Cancer 2006;7:347-350.